These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28482804)

  • 1. Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
    Bundhun PK; Shaik M; Yuan J
    BMC Cardiovasc Disord; 2017 May; 17(1):116. PubMed ID: 28482804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD; Peters RJ; Afzal R; Chrolavicius S; Mehta SR; Fox KA; Granger CB; Franzosi MG; Flather M; Budaj A; Bassand JP; Yusuf S
    Am Heart J; 2009 Mar; 157(3):502-8. PubMed ID: 19249421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Fox KA; Bassand JP; Mehta SR; Wallentin L; Theroux P; Piegas LS; Valentin V; Moccetti T; Chrolavicius S; Afzal R; Yusuf S;
    Ann Intern Med; 2007 Sep; 147(5):304-10. PubMed ID: 17785485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).
    Ross Terres JA; Lozano-Ortega G; Kendall R; Sculpher MJ
    BMC Cardiovasc Disord; 2015 Dec; 15():180. PubMed ID: 26715178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of Parenteral Anticoagulant Therapy in Patients With Myocardial Infarction According to the Russian Register of Acute Myocardial Infarction - REGION-IM.
    Boytsov SA; Shakhnovich RM; Tereschenko SN; Erlikh AD; Pevsner DV; Gulyan RG
    Kardiologiia; 2022 Oct; 62(10):3-15. PubMed ID: 36384404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data.
    Soeiro AM; Silva PG; Roque EA; Bossa AS; César MC; Simões SA; Okada MY; Leal TC; Pedroti FC; Oliveira MT
    Arq Bras Cardiol; 2016 Sep; 107(3):239-244. PubMed ID: 27579543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor Xa inhibitors for acute coronary syndromes.
    Brito V; Ciapponi A; Kwong J
    Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    Budaj A; Eikelboom JW; Mehta SR; Afzal R; Chrolavicius S; Bassand JP; Fox KA; Wallentin L; Peters RJ; Granger CB; Joyner CD; Yusuf S;
    Eur Heart J; 2009 Mar; 30(6):655-61. PubMed ID: 18713759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.
    Schiele F
    Vasc Health Risk Manag; 2010 Apr; 6():179-87. PubMed ID: 20407625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
    Sculpher MJ; Lozano-Ortega G; Sambrook J; Palmer S; Ormanidhi O; Bakhai A; Flather M; Steg PG; Mehta SR; Weintraub W
    Am Heart J; 2009 May; 157(5):845-52. PubMed ID: 19376310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on fondaparinux sodium in acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    BioDrugs; 2008; 22(6):413-5. PubMed ID: 18998758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment elevation.
    Pepe C; Machado M; Olimpio A; Ramos R
    Arq Bras Cardiol; 2012 Jul; 99(1):613-22. PubMed ID: 22735867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux: a pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome.
    McKeage K; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(8):687-98. PubMed ID: 20617858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.